Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 434Carcinoma, Non-Small-Cell Lung 360Neoplasms 339Prostatic Neoplasms 276Colorectal Neoplasms 264Multiple Myeloma 206Lung Neoplasms 195Neoplasm Metastasis 179Leukemia, Myeloid, Acute 160Ovarian Neoplasms 155Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 138Melanoma 126Recurrence 104Head and Neck Neoplasms 99Glioblastoma 99Carcinoma, Renal Cell 98Endometrial Neoplasms 96Carcinoma, Hepatocellular 93Lymphoma, Non-Hodgkin 92Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Lymphoma 91Triple Negative Breast Neoplasms 90Stomach Neoplasms 88Uterine Cervical Neoplasms 85Brain Neoplasms 85Lymphoma, Large B-Cell, Diffuse 80Urinary Bladder Neoplasms 77Glioma 74Leukemia, Lymphocytic, Chronic, B-Cell 73

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lip Neoplasms × 30 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡